Your browser is no longer supported. Please, upgrade your browser.
Heat Biologics, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own4.40% Shs Outstand22.83M Perf Week-3.76%
Market Cap180.63M Forward P/E- EPS next Y-1.13 Insider Trans-9.08% Shs Float21.75M Perf Month2.95%
Income-22.90M PEG- EPS next Q-0.35 Inst Own12.00% Short Float9.31% Perf Quarter-1.16%
Sales4.30M P/S42.01 EPS this Y33.20% Inst Trans32.79% Short Ratio0.72 Perf Half Y-11.52%
Book/sh5.92 P/B1.30 EPS next Y-14.10% ROA-36.50% Target Price- Perf Year13.11%
Cash/sh4.99 P/C1.54 EPS next 5Y- ROE-43.70% 52W Range3.22 - 30.10 Perf YTD43.28%
Dividend- P/FCF- EPS past 5Y49.50% ROI-151.80% 52W High-74.49% Beta0.36
Dividend %- Quick Ratio31.30 Sales past 5Y- Gross Margin- 52W Low138.51% ATR1.15
Employees36 Current Ratio31.30 Sales Q/Q13096.60% Oper. Margin- RSI (14)44.79 Volatility11.57% 12.76%
OptionableYes Debt/Eq0.00 EPS Q/Q66.50% Profit Margin- Rel Volume0.55 Prev Close7.91
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.83M Price7.68
Recom2.00 SMA20-16.67% SMA501.84% SMA200-9.43% Volume1,598,699 Change-2.91%
Mar-03-21Initiated Cantor Fitzgerald Overweight $22
Oct-14-20Initiated B. Riley Securities Buy $4
Jun-20-16Initiated ROTH Capital Buy
Jan-08-16Initiated Noble Financial Buy $16
May-26-15Initiated H.C. Wainwright Buy $13
Sep-18-13Initiated Aegis Capital Buy $36
Feb-16-21 08:08AM  
Feb-12-21 03:00PM  
Feb-10-21 02:44PM  
Feb-09-21 04:22PM  
Jan-27-21 07:30AM  
Jan-26-21 01:53AM  
Jan-20-21 07:30AM  
Jan-19-21 07:30AM  
Jan-11-21 08:00AM  
Jan-08-21 04:00PM  
Dec-16-20 07:30AM  
Dec-10-20 08:00AM  
Nov-30-20 06:48AM  
Nov-09-20 07:00AM  
Oct-30-20 02:40PM  
Oct-28-20 09:33AM  
Oct-07-20 07:30AM  
Sep-16-20 06:37AM  
Sep-09-20 07:30AM  
Sep-02-20 07:30AM  
Aug-30-20 12:41PM  
Aug-26-20 10:00AM  
Aug-24-20 11:14AM  
Aug-13-20 01:54PM  
Aug-12-20 12:47PM  
Aug-11-20 11:27AM  
Aug-07-20 07:00AM  
Aug-05-20 07:30AM  
Aug-03-20 10:00AM  
Jul-30-20 09:07AM  
Jul-29-20 12:05PM  
Jul-27-20 06:30AM  
Jun-22-20 10:54AM  
Jun-20-20 09:49AM  
Jun-18-20 07:30AM  
Jun-08-20 07:30AM  
Jun-04-20 07:30AM  
Jun-01-20 06:15AM  
May-29-20 08:00AM  
May-28-20 11:34AM  
May-27-20 08:00AM  
May-18-20 07:45AM  
May-15-20 09:30AM  
May-14-20 08:00AM  
May-11-20 08:00AM  
Apr-29-20 08:37AM  
Apr-13-20 03:27PM  
Apr-09-20 03:45PM  
Apr-01-20 08:00AM  
Mar-30-20 08:30AM  
Mar-23-20 02:38PM  
Mar-17-20 02:35PM  
Mar-16-20 08:00AM  
Mar-11-20 09:23AM  
Mar-09-20 10:55AM  
Mar-06-20 01:52PM  
Mar-05-20 04:45PM  
Mar-04-20 03:10PM  
Mar-03-20 02:41PM  
Feb-28-20 02:15PM  
Feb-24-20 02:59PM  
Jan-21-20 04:05PM  
Jan-16-20 09:50AM  
Jan-15-20 02:33PM  
Dec-23-19 08:39AM  
Dec-16-19 07:00AM  
Nov-29-19 05:05AM  
Nov-20-19 08:00AM  
Nov-19-19 07:56AM  
Nov-18-19 08:00AM  
Nov-15-19 08:30AM  
Nov-11-19 07:00AM  
Nov-08-19 08:14AM  
Nov-07-19 08:02AM  
Nov-05-19 08:00AM  
Oct-24-19 09:00AM  
Oct-02-19 09:23AM  
Aug-27-19 08:44AM  
Aug-26-19 12:30PM  
Aug-24-19 01:46PM  
Aug-14-19 07:00AM  
Aug-12-19 07:00AM  
Aug-07-19 11:15AM  
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Edward B IIIDirectorNov 12Sale1.03103,304106,4030Nov 13 05:31 PM
Ostrander William L.VP Finance/Corp SecyAug 13Option Exercise0.5215,6258,12515,625Aug 14 06:01 PM